Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 25/5/2017
SIETES contiene 91796 citas

 
 
 1 a 17 de 17 
Presentar resultados
Seleccionar todas
1. Cita con resumen
Gargiulo G, Windecker S, da Costa BR, Feres F, Hong M-K, Gilard M, Kim H-S, Colombo A, Bhatt DL, Kim B-K, Morice M-C, Park KW, Chieffo A, Palmerini T, Stone GW, Valgimigli M. Short term versus long term dual antiplatelet therapy after implantation of drug eluting stent in patients with or without diabetes: systematic review and meta-analysis of individual participant data from randomised trials. BMJ 2016;355:i5483. [Ref.ID 100878]
2.Enlace a cita original Cita con resumen
Leonardi S, Frigoli E, Rothenbühler M, Navarese E, Calabró P, Bellotti P, Briguori C, Ferlini M, Cortese B, Lupi A, Lerna S, Zavallonito-Parenti D, Espposito G, Tresoldi S, Zingarelli A, Rigattieri S, Palmieri C, Liso A, Abate F, Zimarino M, Comeglio M, Gabrielli G, Chieffo A, Brugaletta S, Mauro C, Van Mieghem NM, Heg D, Jüni P, Windecker S, Valgimigli M, for the MATRIX Investigators. Bivalirudin or unfractionated heparin in patients with acute coronary syndromes managed invasively with and without ST elevation (MATRIX): randomised controlled trial. BMJ 2016;354:i4935. [Ref.ID 100794]
3.Tiene citas relacionadas Cita con resumen
Siontis GCM, Stefanini GG, Mavridis D, Siontis KC, Alfonso F, Pérez-Vizcayno MJ, Byrne RA, Kastrati A, Meier B, Salanti G, Jüni P, Windecker S. Percutaneous coronary interventional strategies for treatment of in-stent restenosis: a network meta-analysis. Lancet 2015;386:655-64. [Ref.ID 99406]
4.Tiene citas relacionadas Cita con resumen
Kereiakes DJ, Yeh RW, Massaro JM, Driscoll-Shempp P, Cutlip DE, Steg PG, Gershlick AH, Darius H, Meredith IT, Omiston J, Tanguay JF, Windecker S, Garratt KN, Kandzari DE, Lee DP, Simon Di, Iancu AC, Trebacz J, Mauri L, for the Dual Antiplatelet Therapy (DAPT) Study Investigators. Antiplatelet therapy duration following bare metal or drug-eluting coronary stents. The dual antiplatelet therapy randomized clinical trial. JAMA 2015;313:1113-21. [Ref.ID 98862]
5. Cita con resumen
Pilgrim T, Heg D, Roffi M, Tüller D, Muller O, Vuilliomenet A, Cook S, Weilenmann D, Kaiser C, Jamshidi P, Fahrni T, Moschovitis A, Noble S, Eberli FR, Wenaweser P, Jüni P, Windecker S. Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial. Lancet 2014;384:2111-22. [Ref.ID 98453]
6.Tiene citas relacionadas
Stefanini GG, Windecker S. Stent performance: never too late to sort it out. Lancet 2014;383:2024-6. [Ref.ID 97701]
7.Tiene citas relacionadas
Windecker S, Bax JJ, Mayt A, Stone GW, Marber MS. Future treatment strategies in ST-segment elevation myocardial infarction. Lancet 2013;382:644-57. [Ref.ID 96028]
8. Cita con resumen
Räber L, Kelbaek H, Ostojic M, Baumbach A, Heg D, Tüller D, von Birgelen C, Roffi M, Moschovitis A, Khattab AA, Wenaweser P, Bonvini R, Pedrazzini G, Kornowski R, Weber K, Trelle S, Lüscher TF, Taniwaki M, Matter CM, Meier B, Jüni P, Windecker S, for the COMFORTABLE AMI Trial Investigators. Effect of biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction: the COMFORTABLE AMI randomized trial. JAMA 2012;308:777-87. [Ref.ID 93610]
9.Tiene citas relacionadas Cita con resumen
Stefanini GG, Kalesan B, Serruys PW, Heg D, Buszman P, Linke A, Ischinger T, Klauss V, Eberli F, Wijns W, Morice M-C, Di Mario C, Corti R, Antoni D, Sohn HY, Eerdmans P, Van Es GA, Meier B, Windecker S, Jüni P. Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial. Lancet 2011;378:1940-8. [Ref.ID 91910]
10.Tiene citas relacionadas Cita con resumen
Silber S, Windecker S, Vranckx P, Serruys PW, on behalf of the RESOLUTE All Comers investigators. Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial. Lancet 2011;377:1241-7. [Ref.ID 90368]
11.
Serruys PW, Silber S, Garg S, van Geuns RJ, Richardt G, Buszman PE, Kelbaek H, van Boven AJ, Hofma SH, Linke A, Klauss V, Wijns W, Macaya C, Garot P, DiMario C, Manoharan G, Kornowski R, Ischinger T, Bartorelli A, Ronden J, Bressers M, Gobbens P, Negoita M, van Leeuwen F, Windecker S. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med 2010;363:136-46. [Ref.ID 88811]
12.Tiene citas relacionadas Cita con resumen
Stettler C, Allemann S, Wandel S, Kastrati A, Morice M-C, Schömig A, Pfisterer ME, Stone GW, Leon MB, Suárez de Lezo J, Goy JJ, Park SJ, Sabaté M, Suttorp MJ, Kelbaek H, Spaulding C, Menichelli M, Vermeersch P, Dirksen MT, Cervinka P, De Carlo M, Erglis A, Chechi T, Ortolani P, Schalij MJ, Diem P, Meier B, Windecker S, Jüni P. Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis. BMJ 2008;337:668-72. [Ref.ID 84060]
13.Tiene citas relacionadas
Windecker S, Serruys PW, Wandel S, Buszman P, Trznadel S, Linke A, Lenk K, Ischinger T, Klauss V, Eberli F, Corti R, Wijns W, Morice M-C, Di Mario C, Davies S, van Geuns RJ, Eerdmans P, Van Es GA, Meier B, Jüni P. Biolimus-elugint stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet 2008;372:1163-73. [Ref.ID 84042]
14.Tiene citas relacionadas Cita con resumen
Stettler C, Wandel S, Allemann S, Kastrati A, Morice M-C, Schömig A, Pfisterer ME, Stone GW, Leon MB, Suárez de Lezo J, Goy JJ, Park SJ, Sabaté M, Suttorp MJ, Kelbaek H, Spaulding C, Menichelli M, Vermeersch P, Dirksen MT, Cervinka P, Petronio AS, Nordmann AJ, Diem P, Meier B, Zwahlen M, Reichenbach S, Trelle S, Windecker S, Jüni P. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 2007;370:937-48. [Ref.ID 81082]
15.Tiene citas relacionadas
Daemen J, Wenaweser P, Windecker S, Serruys P. Risks associated with drug-eluting stents. Authors' reply. Lancet 2007;369:1785-6. [Ref.ID 80127]
16.Tiene citas relacionadas Cita con resumen
Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, Kukreja N, Jüni P, Sianos G, Hellige G, van Domburg RT, Hess OM, Boersma E, Meier B, Windecker S, Serruys PW. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007;369:667-78. [Ref.ID 79282]
17.Tiene citas relacionadas
Windecker S, Remondino A, Eberli FR, Jüni P, Räber L, Wenaweser P, Togni M, Billinger M, Tüller D, Seiler C, Roffi M, Corti R, Sütsch G, Maier W, Lüscher TF, Hess OM, Egger M, Meier B. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med 2005;353:653-62. [Ref.ID 74649]
Seleccionar todas
 
 1 a 17 de 17